Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 4, 2011, Pages 495-504

  Hegde, Laxminarayan G ^a   Yu, Cecile ^a   Renner, Travis ^a   Thibodeaux, Harold ^a   Armstrong, Scott R ^a   Park, Timothy ^a   Cheruvu, Madhavi ^a   Olsufka, Rachael ^a   Sandvik, Erik R ^a   Lane, Cassie E ^a   Budman, Joe ^a   Hill, Craig M ^a   Klein, Uwe ^a   Hegde, Sharath S ^a  

^a THERAVANCE INC   (United States)

Author keywords

angioedema; Angiotensin; antihypertensive; DOCA; neprilysin; SHR

Indexed keywords

AMINOPEPTIDASE P; ATRIAL NATRIURETIC FACTOR; BRADYKININ; CANDOXATRIL; CYCLIC GMP; DEOXYCORTICOSTERONE ACETATE; ICATIBANT; MEMBRANE METALLOENDOPEPTIDASE; OMAPATRILAT; VALSARTAN;

ANGIONEUROTIC EDEMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BINDING ASSAY; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXTRAVASATION; DRUG MEGADOSE; HYPERTENSION; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE DRUG DOSE; SPONTANEOUSLY HYPERTENSIVE RAT; TRACHEAL PLASMA EXTRAVASATION; TREATMENT OUTCOME;

ANGIOEDEMA; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; INDANS; MALE; NEPRILYSIN; PROPIONATES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; THIAZEPINES; VALINE;

EID: 79955007122     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318210fc7e     Document Type: Article

References (46)

1. Fryar CD, Hirsch R, Eberhardt MS, et al. Hypertension, high serum total cholesterol, and diabetes: racial and ethnic prevalence differences in US adults 1999-2006. NCHS Data Brief. 2010;36:1-8.
2. Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008;52:818-827.
3. Editorial: State of the heart in the USA. Lancet. 2010;375:697.
4. Kjeldsen SE, Julius S. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angioten-sin receptor blockers. Am Heart J. 2004;148:747-754.
5. Werner C, Baumhaekel M, Teo KK, et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol. 2008;97:418-431.
6. Kurtz TW, Klein U. Next generation of multifunctional angiotensin receptor blockers. Hypertension Res. 2009;32:826-834.
7. Trippodo NC, Robl JA, Asaad MM, et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin converting enzyme BMS-182657 in experimental hypertension and heart failure. JPharmacol Exp Ther. 1995;275:745-752. (Pubitemid 26027044)
8. Vesterqvist O, Reeves RA. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and angiotensin-converting enzyme activity in humans. Curr Hypertens Rep. 2001;3(suppl 2):S22-S27.
9. Weber MA. Vasopeptidase inhibitors Lancet. 2001;358:1525-1532.
10. Regamey F, Maillard M, Nussberger J, et al. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men. Hypertension. 2002;40: 266-272. (Pubitemid 35006709)
11. Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension. 2003;41:383-389. (Pubitemid 36314604)
12. Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. JHypertens Suppl. 1999;17:S37-S43. (Pubitemid 29116667)
13. Kostis JB, Packer M, BlackHR, et al. Omapatrilat andenalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am JHypertens. 2004;17:103-111. (Pubitemid 38125125)
14. Bani M, Colantoni A, Guillaume M, et al. A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers. BrJ Clin Pharmacol. 2000;50:338-349.
15. Johnson AG, Pearce GL, Danoff TM. A randomized double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of dual ACE/NEP inhibitor GW660511X in mild to moderate hypertensive patients. JHum Hypertens. 2006;20:496-503. (Pubitemid 43923119)
16. Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. JAMA. 1997;278:232-323.
17. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet. 2000;356:608-609. (Pubitemid 30627581)
18. Weber MA, Messerli FH. Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension. 2008;51:1465-1467.
19. Miller DR, Oliveria SA, Berlowitz DR, et al. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51:1624-1630.
20. Hoover T, Lippmann M, Grouzmann E, et al. Angiotensin converting enzyme inhibitor induced angio-edema: a review of pathophysiology and risk factors. Clin Exp Allergy. 2010;40:50-61.
21. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693-1697. (Pubitemid 28254530)
22. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. ImmunolAllergy Clin North Am. 2006;26:725-737. (Pubitemid 44679724)
23. Byrd JB, Touzin K, Sile S, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension. 2008; 51:141-147. (Pubitemid 350307116)
24. Deddish PA, Marcic BM, Tan F, et al. Neprilysin inhibitors potentiate effects of bradykinin B2 receptor. Hypertension. 2002;39:619-623. (Pubitemid 34165194)
25. Brown NJ, Byiers S, Carr D, et al. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE-inhibitor associated angioedema. Hypertension. 2009;54:516-523.
26. Fryer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008; 153:947-955. (Pubitemid 351328937)
27. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16-29. (Pubitemid 351664943)
28. Gavras I, Gavras H. Are patients who develop angioedema with ACE inhibition at risk of the same problem with AT1 receptor blockers? Arch Intern Med. 2003;163:240-241. (Pubitemid 36120194)
29. Haymore BR, Yoon J, Mikita CP, et al. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol. 2008;101:495-499.
30. Yusuf S, Teo KK, Pogue J, et al. and ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. NEngl J Med. 2008;358:1547-1559. (Pubitemid 351522739)
31. Gardiner SM, March JE, Kemp PA, et al. Regional hemodynamic effects of neutral endopeptidase inhibition and angiotensin (AT(1)) receptor antagonism alone or in combination in conscious spontaneously hypertensive rats. J Pharmacol Exp Ther. 2006;319:340-348. (Pubitemid 44455141)
32. Pu Q, Brassard P, Javeshghani DM, et al. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. J Hypertens. 2008;26:322-333.
33. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401-414.
34. Ruilope LM, Dukat A, Bohm M, et al. Blood pressure reduction with LCZ696 a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomized, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255-1266.
35. Seymour AA, Asad MM, Abboa-Offei BE, et al. Determinants of in vivo activity ofneutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors. J Pharmacol Exp Ther. 1996;276:708-713. (Pubitemid 126660511)
36. Sulpizio AC, Pullen MA, Edwards RM, et al. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 in-hibition on plasma extravasation in the rat JPharmacol Exp Ther. 2004; 309:1141-1147. (Pubitemid 38669702)
37. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099-3108.
38. Trippodo NC, Robl JA, Asaad MM, et al. Effects of omapatrilat in low, normal and high renin experimental hypertension. Am JHypertens. 1998; 11:363-372. (Pubitemid 28186749)
39. Pu Q, Amiri F, Gannon P, et al. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. J Hypertens. 2005;23: 401-409. (Pubitemid 40279644)
40. Pu Q, Touyz RM, Schiffrin EL. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats. JHypertens. 2002;20:899-907. (Pubitemid 34913671)
41. Bäcklund T, Palojoki E, Grönholm T, et al. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo. Pharmacol Res. 2001;44:411-418. (Pubitemid 33105081)
42. Pu Q, Schiffrin EL. Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats. Am J Hyper-tens. 2001;14:1067-1072. (Pubitemid 32978081)
43. Ferrario CM, Smith RD, Brosnihan B, et al. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am J Hypertens. 2002;15:557-564. (Pubitemid 34596964)
44. Smith RE, Ashiya M. Antihypertensive therapies. Nat Rev Drug Discov. 2007;6:597-598. (Pubitemid 47202484)
45. Zhang X, Xiang B. Discontinued drugs in 2008: cardiovascular drugs. Exper Opin Investg Drugs. 2009;18:875-885.
46. Lötvall JO, Tokuyama K, Barnes PJ, et al. Bradykinin-induced airway microvascular leakage is potentiated by captopril and phosphoramidon. EurJPharmacol. 1991;200:211-217.